Fatih Asutay, Yusuf Atalay, [...], and Ahmet Hüseyin Acar
Reference
(Ref ID:) PMC5516743
Chosen Image filename: PMC5516743_Table_02.jpg
Document structure and format:
Title: Summary of Research Paper on "The Evaluation of the Clinical Effects of Botulinum Toxin on Nocturnal Bruxism"
I. Introduction The research paper titled "The Evaluation of the Clinical Effects of Botulinum Toxin on Nocturnal Bruxism" investigates the efficacy of botulinum toxin A (BTXA) in the treatment of nocturnal bruxism. Nocturnal bruxism refers to abnormal maxillomandibular activity during sleep, characterized by grinding and clenching of the teeth. The paper aims to assess the clinical effects of BTXA on pain reduction in patients who have not responded to conservative treatment.
II. Methodology The study was conducted using a retrospective design and included 25 female patients aged 23-55 years. All patients received a single injection of BTXA in the right and left masseters. Data collection involved evaluating Visual Analogue Scale (VAS) values, complaint duration, onset of effect, and duration of effectiveness. Statistical analysis was performed using the Statistical Package for the Social Science Program.
III. Results The results of the study indicated that BTXA produced significant improvements in pain scores among the patients. Only 2 adverse events (8%) were recorded, and there were no significant changes in maximum mouth opening. The mean duration of the complaint before injection was 8.84 ± 4.57 years, and the time of onset of effect was 12.24 ± 2.02 days. The time of onset of the loss of BTXA effectiveness was 4.76 ± 1.01 months.
IV. Discussion The findings of the study suggest that BTXA is effective in the treatment of nocturnal bruxism, as it significantly reduced pain scores in the patients. The use of BTXA for bruxism treatment has been supported by previous studies, although there is limited evidence available. It is important to note that this study has some limitations, such as the small sample size and the retrospective design. Further research is needed to confirm and expand on these findings.
V. Conclusion In conclusion, the research paper provides evidence for the effectiveness of BTXA in reducing pain in patients with nocturnal bruxism. Despite the study's limitations, the results contribute to the understanding of BTXA as a potential treatment option for this condition. Further research in larger samples and with different methodologies is needed to validate these findings and explore additional aspects of BTXA treatment for nocturnal bruxism.
Comments